{ "run": { "id": "cmnr1592w06gbp658lubo8fx9", "region": "US", "assetId": "cmnr1592g06g4p658lhiuznm0", "ticker": "TECH", "snapshotId": "cmnr1592m06g7p658t762nczd", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:55.254Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr1592m06g7p658t762nczd", "assetId": "cmnr1592g06g4p658lhiuznm0", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 55.82, "price": 55.21, "dayLow": 53.87, "volume": 2011249, "dayHigh": 56.9, "currency": "USD", "prevClose": 53.83, "week52Low": 46.01, "week52High": 72.16 }, "fundamentals": { "pe": 109.468085106383, "beta": 1.1512462827634, "epsTTM": 0.47, "fcfTTM": 183088000, "growth": { "epsYoy": -0.5607476635514019, "revenueYoy": -0.7574052892873687 }, "sector": "Biological Products, (No Diagnostic Substances)", "margins": { "net": 0.1284621650212757, "gross": 0.6464747175346512, "operating": 0.1840663518962271 }, "website": "http://bio-techne.com", "industry": "Biotechnology", "pegRatio": -1.95218085106383, "ebitdaTTM": 266169000, "forwardPe": 30.8083832335329, "marketCap": 11400000000, "totalCash": 172879000, "totalDebt": 520000000, "debtEquity": 0.360640564350368, "quickRatio": 2.545774998931822, "revenueTTM": 295877000, "companyName": "BIO-TECHNE Corp", "priceToBook": 3.40234710554366, "currentRatio": 4.539273353937305, "dividendYield": 0.00621769103561424, "returnOnAssets": 0.01506679948737443, "returnOnEquity": 0.0382529153516141, "analystOpinions": null, "businessSummary": "Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.", "enterpriseValue": 8634269450, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 3100, "sharesOutstanding": 156453292, "enterpriseToEbitda": 32.43904981421578, "analystTargetMedian": null, "enterpriseToRevenue": 29.18195550853902, "operatingCashflowTTM": 109996000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:55.246Z" }, "results": [ { "id": "cmnr1592y06gfp6585dy0qjuk", "runId": "cmnr1592w06gbp658lubo8fx9", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"TECH\",\"currency\":\"USD\",\"current_price\":55.21,\"target_price_6m\":56.0,\"target_price_12m\":57.5,\"recommendation\":\"HOLD\",\"confidence\":0.5,\"thesis_bullets\":[\"Post-divestiture revenue base creates transition uncertainty and valuation complexity\",\"Forward P/E of ~31x prices in significant earnings recovery already\",\"Strong FCF generation ($183M TTM) supports balance sheet resilience\",\"Revenue down ~76% YoY likely from asset divestitures, not organic weakness\",\"Elevated EV/EBITDA of 32x limits upside without meaningful earnings acceleration\"],\"key_drivers\":[{\"driver\":\"Post-divestiture organic revenue growth trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Protein Sciences segment margin expansion potential\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biotech end-market funding environment recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated trailing P/E (109x) signals earnings trough\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt load of $520M vs $173M cash constrains flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong gross margins (~64.5%) on remaining business\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low ROA (1.5%) and ROE (3.8%) reflect transition drag\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Share count dilution risk from potential M&A\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Prolonged biotech funding downturn reduces reagent/instrument demand\",\"Integration or operational disruption from portfolio restructuring\",\"Competitive pricing pressure from larger life sciences peers\",\"Higher-for-longer rates compress biotech tool multiples further\",\"Key customer concentration or contract losses in biopharma\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.22,\"wacc\":0.095,\"terminal_multiple\":28},\"scenarios\":{\"bear\":{\"target_price\":44.0,\"prob\":0.2,\"notes\":\"Biotech funding remains weak; organic growth stalls, multiple compresses to 24x.\"},\"base\":{\"target_price\":57.5,\"prob\":0.55,\"notes\":\"Modest organic recovery (mid-single digit); margins improve slightly post-divestiture.\"},\"bull\":{\"target_price\":70.0,\"prob\":0.25,\"notes\":\"Strong biopharma recovery drives high-single digit growth; multiple re-rates to 33x+.\"}},\"method_notes\":\"Blended EV/EBITDA and forward P/E approach on post-divestiture earnings power. Revenue decline appears divestiture-driven (not organic). Forward P/E of ~31x already prices moderate recovery, limiting near-term upside. Expected 12M return ~4% falls in HOLD range. Confidence is low given restructured revenue base uncertainty and rich multiples. Probability-weighted scenario value (~$57.7) aligns with base target. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Prolonged biotech funding downturn reduces reagent/instrument demand", "Integration or operational disruption from portfolio restructuring", "Competitive pricing pressure from larger life sciences peers", "Higher-for-longer rates compress biotech tool multiples further", "Key customer concentration or contract losses in biopharma" ], "ticker": "TECH", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Modest organic recovery (mid-single digit); margins improve slightly post-divestiture.", "target_price": 57.5 }, "bear": { "prob": 0.2, "notes": "Biotech funding remains weak; organic growth stalls, multiple compresses to 24x.", "target_price": 44 }, "bull": { "prob": 0.25, "notes": "Strong biopharma recovery drives high-single digit growth; multiple re-rates to 33x+.", "target_price": 70 } }, "confidence": 0.5, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.07, "terminal_multiple": 28, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Post-divestiture organic revenue growth trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Protein Sciences segment margin expansion potential", "impact": "HIGH", "direction": "POS" }, { "driver": "Biotech end-market funding environment recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated trailing P/E (109x) signals earnings trough", "impact": "MED", "direction": "NEG" }, { "driver": "Debt load of $520M vs $173M cash constrains flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Strong gross margins (~64.5%) on remaining business", "impact": "MED", "direction": "POS" }, { "driver": "Low ROA (1.5%) and ROE (3.8%) reflect transition drag", "impact": "MED", "direction": "NEG" }, { "driver": "Share count dilution risk from potential M&A", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended EV/EBITDA and forward P/E approach on post-divestiture earnings power. Revenue decline appears divestiture-driven (not organic). Forward P/E of ~31x already prices moderate recovery, limiting near-term upside. Expected 12M return ~4% falls in HOLD range. Confidence is low given restructured revenue base uncertainty and rich multiples. Probability-weighted scenario value (~$57.7) aligns with base target. Not investment advice.", "current_price": 55.21, "recommendation": "HOLD", "thesis_bullets": [ "Post-divestiture revenue base creates transition uncertainty and valuation complexity", "Forward P/E of ~31x prices in significant earnings recovery already", "Strong FCF generation ($183M TTM) supports balance sheet resilience", "Revenue down ~76% YoY likely from asset divestitures, not organic weakness", "Elevated EV/EBITDA of 32x limits upside without meaningful earnings acceleration" ], "target_price_6m": 56, "target_price_12m": 57.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 41815, "createdAt": "2026-04-09T05:21:55.254Z", "usage": { "inputTokens": 3561, "outputTokens": 1854, "costUsd": 0.064155 } }, { "id": "cmnr1592y06gip658srj3tu4m", "runId": "cmnr1592w06gbp658lubo8fx9", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research AI\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TECH\",\n \"currency\": \"USD\",\n \"current_price\": 55.21,\n \"target_price_6m\": 58.0,\n \"target_price_12m\": 60.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue stabilization from new product launches.\",\n \"Margin gains via operational efficiencies.\",\n \"Strong balance sheet supports strategic investments.\",\n \"Sector tailwinds from increased R&D spending.\",\n \"Forward valuation suggests moderate upside potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"New product pipeline development\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Revenue growth recovery\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operating margin expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt management and cash flow\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approval timelines\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive market dynamics\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Clinical trial setbacks\", \"Regulatory delays\", \"Economic sensitivity\", \"Execution risks on new products\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.085,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 50.0, \"prob\": 0.2, \"notes\": \"Revenue declines continue with margin pressure.\" },\n \"base\": { \"target_price\": 60.0, \"prob\": 0.6, \"notes\": \"Steady recovery in growth and profitability.\" },\n \"bull\": { \"target_price\": 70.0, \"prob\": 0.2, \"notes\": \"Accelerated adoption driving above-guidance performance.\" }\n },\n \"method_notes\": \"DCF with 5% revenue CAGR, 20% EBIT margin, 8.5% WACC, terminal multiple 25x. BUY for 8.7% 12M upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Equity Research AI", "risks": [ "Clinical trial setbacks", "Regulatory delays", "Economic sensitivity", "Execution risks on new products" ], "ticker": "TECH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady recovery in growth and profitability.", "target_price": 60 }, "bear": { "prob": 0.2, "notes": "Revenue declines continue with margin pressure.", "target_price": 50 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption driving above-guidance performance.", "target_price": 70 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 25, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "New product pipeline development", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Debt management and cash flow", "impact": "LOW", "direction": "POS" }, { "driver": "Regulatory approval timelines", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive market dynamics", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF with 5% revenue CAGR, 20% EBIT margin, 8.5% WACC, terminal multiple 25x. BUY for 8.7% 12M upside. Not investment advice.", "current_price": 55.21, "recommendation": "BUY", "thesis_bullets": [ "Revenue stabilization from new product launches.", "Margin gains via operational efficiencies.", "Strong balance sheet supports strategic investments.", "Sector tailwinds from increased R&D spending.", "Forward valuation suggests moderate upside potential." ], "target_price_6m": 58, "target_price_12m": 60 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 356, "createdAt": "2026-04-09T05:21:55.254Z", "usage": { "inputTokens": 2074, "outputTokens": 4097, "costUsd": 0.002301 } }, { "id": "cmnr1592y06ggp658og3q4xh1", "runId": "cmnr1592w06gbp658lubo8fx9", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TECH\",\n \"currency\": \"USD\",\n \"current_price\": 55.21,\n \"target_price_6m\": 56.00,\n \"target_price_12m\": 58.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Forward P/E of 31x implies strong earnings recovery expectations despite recent massive revenue contraction.\",\n \"TTM revenue dropped 75% YoY, highlighting severe end-market destocking or post-pandemic normalization headwinds.\",\n \"Strong gross margins (64.6%) and FCF generation ($183M) provide a solid fundamental floor.\",\n \"Healthy balance sheet with current ratio of 4.5x mitigates near-term liquidity risks.\",\n \"Valuation appears full at current levels, balancing recovery potential against execution risks.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biopharma end-market demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Inventory destocking trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Reagent pricing power\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"China market recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Academic funding environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration and synergies\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged biopharma funding constraints reducing R&D tool spend.\",\n \"Slower than expected recovery in China weighing on regional sales.\",\n \"Failure to achieve forward EPS estimates, leading to multiple compression.\",\n \"Increased competition in spatial biology and proteomics.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.085,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 42.00,\n \"prob\": 0.3,\n \"notes\": \"Destocking persists and biopharma R&D budgets contract further, compressing multiples.\"\n },\n \"base\": {\n \"target_price\": 58.00,\n \"prob\": 0.5,\n \"notes\": \"Gradual end-market recovery allows TECH to meet forward EPS estimates of ~$1.80.\"\n },\n \"bull\": {\n \"target_price\": 70.00,\n \"prob\": 0.2,\n \"notes\": \"Rapid biotech funding rebound and strong spatial biology adoption drive earnings beat.\"\n }\n },\n \"method_notes\": \"Valuation based on 32x forward P/E applied to normalized EPS estimates, blended with a DCF (8.5% WACC, 25x terminal multiple). The massive TTM revenue contraction warrants caution, balancing recovery hopes against execution risk. Recommendation is HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation", "risks": [ "Prolonged biopharma funding constraints reducing R&D tool spend.", "Slower than expected recovery in China weighing on regional sales.", "Failure to achieve forward EPS estimates, leading to multiple compression.", "Increased competition in spatial biology and proteomics." ], "ticker": "TECH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual end-market recovery allows TECH to meet forward EPS estimates of ~$1.80.", "target_price": 58 }, "bear": { "prob": 0.3, "notes": "Destocking persists and biopharma R&D budgets contract further, compressing multiples.", "target_price": 42 }, "bull": { "prob": 0.2, "notes": "Rapid biotech funding rebound and strong spatial biology adoption drive earnings beat.", "target_price": 70 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.08, "terminal_multiple": 25, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Biopharma end-market demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Inventory destocking trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Reagent pricing power", "impact": "MED", "direction": "POS" }, { "driver": "China market recovery", "impact": "MED", "direction": "POS" }, { "driver": "Academic funding environment", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration and synergies", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on 32x forward P/E applied to normalized EPS estimates, blended with a DCF (8.5% WACC, 25x terminal multiple). The massive TTM revenue contraction warrants caution, balancing recovery hopes against execution risk. Recommendation is HOLD. Not investment advice.", "current_price": 55.21, "recommendation": "HOLD", "thesis_bullets": [ "Forward P/E of 31x implies strong earnings recovery expectations despite recent massive revenue contraction.", "TTM revenue dropped 75% YoY, highlighting severe end-market destocking or post-pandemic normalization headwinds.", "Strong gross margins (64.6%) and FCF generation ($183M) provide a solid fundamental floor.", "Healthy balance sheet with current ratio of 4.5x mitigates near-term liquidity risks.", "Valuation appears full at current levels, balancing recovery potential against execution risks." ], "target_price_6m": 56, "target_price_12m": 58 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 27679, "createdAt": "2026-04-09T05:21:55.254Z", "usage": { "inputTokens": 2427, "outputTokens": 856, "costUsd": 0.015126 } }, { "id": "cmnr1592y06gep658cx467rzg", "runId": "cmnr1592w06gbp658lubo8fx9", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"TECH\",\"currency\":\"USD\",\"current_price\":55.21,\"target_price_6m\":56.8,\"target_price_12m\":58,\"recommendation\":\"HOLD\",\"confidence\":0.59,\"thesis_bullets\":[\"High gross margins and strong liquidity support resilience through research spending softness.\",\"Forward earnings recovery could normalize valuation faster than trailing metrics imply.\",\"Premium multiple already discounts a meaningful rebound in instruments and bioprocessing.\",\"Snapshot shows sharp YoY declines, limiting near-term estimate confidence.\",\"Risk/reward appears balanced after the stock's pullback from 52-week highs.\"],\"key_drivers\":[{\"driver\":\"Academic and biopharma funding trends\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Instrument placements recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Bioprocessing demand normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin restoration from mix and costs\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation versus growth\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Continued post-COVID revenue resets\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Balance sheet flexibility\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"End-market funding stays weak longer.\",\"Recovery in bioprocessing and instruments disappoints.\",\"Multiple compression from high rates or derating.\",\"Snapshot fundamental inconsistencies reduce forecast reliability.\"],\"assumptions\":{\"revenue_cagr_3y\":8,\"ebit_margin_target\":23.5,\"wacc\":8.8,\"terminal_multiple\":24},\"scenarios\":{\"bear\":{\"target_price\":44,\"prob\":0.25,\"notes\":\"Funding remains soft and the premium multiple compresses further.\"},\"base\":{\"target_price\":58,\"prob\":0.5,\"notes\":\"Gradual demand normalization supports modest growth and some margin recovery.\"},\"bull\":{\"target_price\":70,\"prob\":0.25,\"notes\":\"Research demand rebounds faster and premium valuation remains intact.\"}},\"method_notes\":\"Base case triangulates forward P/E and EV/EBITDA versus quality life-science tools peers and normalized margins. Used snapshot quote fields exactly; snapshot fundamentals appear internally inconsistent on revenue/EBITDA, so confidence is moderate and targets stay near fair value. No sell-side price targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI o3", "risks": [ "End-market funding stays weak longer.", "Recovery in bioprocessing and instruments disappoints.", "Multiple compression from high rates or derating.", "Snapshot fundamental inconsistencies reduce forecast reliability." ], "ticker": "TECH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual demand normalization supports modest growth and some margin recovery.", "target_price": 58 }, "bear": { "prob": 0.25, "notes": "Funding remains soft and the premium multiple compresses further.", "target_price": 44 }, "bull": { "prob": 0.25, "notes": "Research demand rebounds faster and premium valuation remains intact.", "target_price": 70 } }, "confidence": 0.59, "assumptions": { "wacc": 8.8, "revenue_cagr_3y": 8, "terminal_multiple": 24, "ebit_margin_target": 23.5 }, "key_drivers": [ { "driver": "Academic and biopharma funding trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Instrument placements recovery", "impact": "MED", "direction": "POS" }, { "driver": "Bioprocessing demand normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin restoration from mix and costs", "impact": "MED", "direction": "POS" }, { "driver": "Premium valuation versus growth", "impact": "HIGH", "direction": "NEG" }, { "driver": "Continued post-COVID revenue resets", "impact": "HIGH", "direction": "NEG" }, { "driver": "Balance sheet flexibility", "impact": "LOW", "direction": "POS" } ], "method_notes": "Base case triangulates forward P/E and EV/EBITDA versus quality life-science tools peers and normalized margins. Used snapshot quote fields exactly; snapshot fundamentals appear internally inconsistent on revenue/EBITDA, so confidence is moderate and targets stay near fair value. No sell-side price targets used; not investment advice.", "current_price": 55.21, "recommendation": "HOLD", "thesis_bullets": [ "High gross margins and strong liquidity support resilience through research spending softness.", "Forward earnings recovery could normalize valuation faster than trailing metrics imply.", "Premium multiple already discounts a meaningful rebound in instruments and bioprocessing.", "Snapshot shows sharp YoY declines, limiting near-term estimate confidence.", "Risk/reward appears balanced after the stock's pullback from 52-week highs." ], "target_price_6m": 56.8, "target_price_12m": 58 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_054acf62c1faedcd0069d75dc52a948195af972a02977fdce0", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 34927, "createdAt": "2026-04-09T05:21:55.254Z", "usage": { "inputTokens": 2347, "outputTokens": 2010, "costUsd": 0.032247 } }, { "id": "cmnr1592y06ghp658y7ettjnd", "runId": "cmnr1592w06gbp658lubo8fx9", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Fundamental DCF Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TECH\",\n \"currency\": \"USD\",\n \"current_price\": 55.21,\n \"target_price_6m\": 56.5,\n \"target_price_12m\": 58,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"High 32x EV/EBITDA multiple caps upside potential.\",\n \"Sharp YOY revenue and EPS declines highlight risks.\",\n \"Strong moat in life sciences reagents and instruments.\",\n \"Forward recovery in bioprocessing assumed in valuation.\",\n \"Mixed evidence and fair value lead to HOLD rating.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Bioprocessing demand recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Biotech R&D budget trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Continued revenue decline\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"EBIT margin improvement\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Intense industry competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Economic impact on lab spending\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Successful product innovation\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged biotech funding winter\",\n \"Multiple contraction from high valuation\",\n \"Supply chain and operational issues\",\n \"Loss of market share to competitors\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 8,\n \"ebit_margin_target\": 25,\n \"wacc\": 9.5,\n \"terminal_multiple\": 30\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 42,\n \"prob\": 0.35,\n \"notes\": \"Persistent negative growth triggers de-rating.\"\n },\n \"base\": {\n \"target_price\": 58,\n \"prob\": 0.45,\n \"notes\": \"Gradual recovery aligns with forward multiples.\"\n },\n \"bull\": {\n \"target_price\": 75,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth exceeds expectations.\"\n }\n },\n \"method_notes\": \"DCF using assumed 8% 3Y revenue CAGR, 25% EBIT margin target, 9.5% WACC and 30x terminal multiple. Mixed growth and rich valuation yield modest upside consistent with HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Fundamental DCF Model", "risks": [ "Prolonged biotech funding winter", "Multiple contraction from high valuation", "Supply chain and operational issues", "Loss of market share to competitors" ], "ticker": "TECH", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Gradual recovery aligns with forward multiples.", "target_price": 58 }, "bear": { "prob": 0.35, "notes": "Persistent negative growth triggers de-rating.", "target_price": 42 }, "bull": { "prob": 0.2, "notes": "Accelerated growth exceeds expectations.", "target_price": 75 } }, "confidence": 0.62, "assumptions": { "wacc": 9.5, "revenue_cagr_3y": 8, "terminal_multiple": 30, "ebit_margin_target": 25 }, "key_drivers": [ { "driver": "Bioprocessing demand recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Biotech R&D budget trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Continued revenue decline", "impact": "HIGH", "direction": "NEG" }, { "driver": "EBIT margin improvement", "impact": "MED", "direction": "POS" }, { "driver": "Intense industry competition", "impact": "MED", "direction": "NEG" }, { "driver": "Economic impact on lab spending", "impact": "MED", "direction": "NEG" }, { "driver": "Successful product innovation", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using assumed 8% 3Y revenue CAGR, 25% EBIT margin target, 9.5% WACC and 30x terminal multiple. Mixed growth and rich valuation yield modest upside consistent with HOLD. Not investment advice.", "current_price": 55.21, "recommendation": "HOLD", "thesis_bullets": [ "High 32x EV/EBITDA multiple caps upside potential.", "Sharp YOY revenue and EPS declines highlight risks.", "Strong moat in life sciences reagents and instruments.", "Forward recovery in bioprocessing assumed in valuation.", "Mixed evidence and fair value lead to HOLD rating." ], "target_price_6m": 56.5, "target_price_12m": 58 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "50096479-eec3-9711-a08a-b5198f2a4716", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 16281, "createdAt": "2026-04-09T05:21:55.254Z", "usage": { "inputTokens": 2684, "outputTokens": 3987, "costUsd": 0.067857 } } ] } }